Image of Fondaparinux:  A Pharmacoeconomic Review of its Use in the Management of Non-ST-Segment Elevation Acute Coronary Syndrome

LITERATURE

Fondaparinux: A Pharmacoeconomic Review of its Use in the Management of Non-ST-Segment Elevation Acute Coronary Syndrome


In OASIS-5, a large pivotal trial in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), subcutaneous fondaparinux 2.5 mg once daily was noninferior to subcutaneous enoxaparin 1mg/kg twice daily (both agents were administered over a mean of about 5 days in combination with antiplatelet therapy) in reducing death or ischaemic events at 9 days, and the efficacy was maintained for up to 6 months (study end). However, fondaparinux was associated with a significantly lower rate of bleeding than enoxaparin in the first 9 days, and at 3 and 6 months. This lower rate of bleeding led to lower longterm mortality and morbidity with fondaparinux than with enoxaparin.


Availability

Diviti-007Available

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Pharmacoeconomics 2010; 28 (8): 687-698
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous